D

✔ Free Priority Shipping Orders +$150

D

✔ 3rd-Party Tested

D

✔ 20K Products Sold

(813) 355-9001

Largo, FL USA

IGF1-LR3 1mg

$89.99

438 in stock (can be backordered)

1 Vial
MOST POPULAR
$84.99
2 Vials
TOP RATED
$145.99
$169.98
3 Vials
BEST CHOICE
$207.99
$254.97
4 Vials
$262.99
$339.96
5 Vials
$311.99
$424.95
10 Vials
$591.99
$849.90
20 Vials
$1,124.99
$1,699.80
40 Vials
$2,136.99
$3,399.60
100 Vials
$5,074.99
$8,499.00
Availability: Ships today if ordered and paid by 7AM EST

Where to buy IGF1-LR3? Shop now for IGF1-LR3 with exceptional quality and get more for less with our bulk sales. Quick 48-hour delivery available.

IGF-1 LR3 1mg Properties

Chemical Formula: C400H625N111O115S9
Molecular Mass: 9117.60
Synonyms: Long R3-IGF-1, M9L22Y19H9, 143045-27-6, Long-(arg3)insulin-like growth factor-i
CAS Number: 143045-27-6
PubChem: 381123731
Total Amount of the Active Ingredient: 1mg (1 vial)
Shelf Life: 36 months

Product Quality

Lab tests are occasionally published on the website.

You can have the product you bought from us tested at any HPLC licensed testing facility and if the results are negative, we will refund the following:

Cost of HPLC test

Total amount of the order + shipping fee

Peer-Reviewed Studies

Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers

Abstract
Insulin-like growth factor-1 (IGF-1) is perhaps the most important endogenous factor controlling growth. Most studies to date in livestock have shown that IGF-1 has greatest efficacy when animals are in a catabolic state. We have determined the effects of an i.v. infusion of the IGF-1 analog Long(R3)-IGF-1 on protein metabolism in beef heifers that were slowly losing liveweight because of restricted feeding. There was a tendency for both whole-body protein and skeletal muscle protein to be conserved in Long(R3)-IGF-1-treated heifers. Long(R3)-IGF-1 administration markedly reduced the plasma concentrations of all amino acids measured and glucose. There was a significant change in the profile differences of endogenous plasma IGF-1 concentrations during the 8-hr infusion period, with plasma IGF-1 decreasing sharply in the test group. There was a significant difference in mean profiles for plasma IGF-2 between the test and control groups. Overall, plasma IGF-2 for the control group decreased only slightly over time (about 40 ng/ml), whereas the test group decreased dramatically (by about 140 ng/ml). Increased plasma concentrations of a 31-32-kDa IGF-binding protein (possibly IGF-binding protein-1) in the treated group was detected by radioligand blot. We found that Long(R3)-IGF-1 infusion tended to preserve whole-body and muscle protein in beef heifers on a low-quality diet, and suggest that further investigation of this treatment may provide an alternative approach to reducing weight loss during the dry season.


Porcine growth hormone and LongR(3)IGF-I can improve recovery from surgery-induced weight loss in guinea pigs.

Abstract
In the present study, porcine growth hormone (pGH) and LongR(3)IGF-I (LR(3)IGF-I), a potent analogue of IGF-I, were infused continuously into 430-g guinea pigs for 7 days, either alone or in combination, to examine whether pGH can counteract the reduction in circulating IGF-I concentrations induced by LR(3)IGF-I administration. The pGH and LR(3)IGF-I were infused at rates of 400 microg/day (0.93 mg/kg/day) and 120 microg/day (0.28 mg/kg/day), respectively, by miniosmotic pumps. The same doses were infused in the combination treatment. During the first day of treatment, animals lost between 2 and 3% of body weight. Cumulative body weight gains as a percentage of initial body weight were significantly (P < 0.001) increased relative to vehicle-treated controls by the LR(3)IGF-I, pGH, and combination treatments when effects were analyzed across the whole 7-day treatment period. The increased weight gains relative to controls were largely made on day 2, but these gains were not associated with increased water or feed intakes, indicating that pGH and LR(3)IGF-I improved feed conversion efficiency. LR(3)IGF-I alone or in combination with pGH significantly increased the fractional weight of kidneys at the end of the 7-day treatment period, whereas LR(3)IGF-I alone increased the fractional weight of spleens. Concentrations of IGF-I in serum collected after 7 days of treatment were decreased by LR(3)IGF-I, but this decrease was not ameliorated by coinfusion with pGH. GH alone did not have any effects on IGF-I concentration. This study suggests that pGH does not have a strong influence on circulating IGF-I concentrations in the guinea pig. We have also demonstrated that pGH and LR(3)IGF-I are capable of enhancing the recovery of body weight lost in response to surgery in the guinea pig.


Insulin-like growth factor-I (IGF-I) analogue, LR(3)IGF-I, ameliorates the loss of body weight but not of skeletal muscle during food restriction

Abstract
Insulin-like growth factor-I (IGF-I) is known to have anabolic effects in freely fed rats. We have investigated the ability of infused LR(3)IGF-I, an analogue of IGF-I, to attenuate the loss of lean tissue due to food restriction in young (5 weeks) and adult (12 weeks) rats. Groups of rats received food at 100%, 78%, 56% or 33% of ad libitum levels. Within each nutrition group the rats were continuously infused with LR(3)IGF-I at (98 nmol/day)/kg body weight or vehicle for 7 days. At each level of food intake, rats infused with LR(3)IGF-I maintained higher body weight (around 3-8%;P< 0.001) and nitrogen retention (P< 0.001) than those infused with vehicle alone but muscle protein was not conserved. LR(3)IGF-I infusion increased fat loss only in young rats (P< 0.05) despite a reduction in plasma insulin levels in both age groups (P< 0.01). Muscle protein turnover rates were unaffected by LR(3)IGF-I in young rats. In adult rats LR(3)IGF-I exacerbated the effects of food restriction through increased rates of protein breakdown, reduced RNA content and reduced rates of protein synthesis (P< 0.05) despite their larger fat reserves. Although young and adult rats show differing metabolic responses, we conclude that infusion of LR(3)IGF-I to either group during short-term food restriction does not ameliorate the loss of lean tissue by allowing more efficient utilization and/or partitioning of nutrients.


Shipping

USA

Canada

If your shipment was seized (International Orders), we will provide a 50% discount applicable on your next purchase. Please contact us for more information.

Disclaimer

The information provided above is not intended to substitute medical advice, diagnosis, or treatment. Should you have any questions regarding a medical condition, seek the advice of your physician or a qualified healthcare provider.

In no case should medical advice be disregarded or delayed because of what you have read or seen. We bear no responsibility or liability for your use of any of our research compounds and products. Please note that they are being sold for research purposes ONLY. We do NOT condone any personal use.

Note: In some cases wherein the assigned top colors are out of stock, a different top color will be used to ensure that your order will not be delayed. Should you need assistance identifying the peptide vial that you received, please send us an email at [email protected].

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: “in glass”) are performed outside the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat and/or cure any medical condition, ailment or disease. Bodily introduction of any kind into animals or human is strictly prohibited by law.

Additional information

Weight 10 oz
Dimensions 0.2 × .2 × .2 in

FAQ

IGF1-LR3 1mg Vials  

How to reconstitute IGF1-LR3 1mg vials?

IGF1-LR3 1mg vials contain a peptide powder, which is typically a puck or loose bits due to shipping. To reconstitute a IGF1-LR3 1mg vials, researchers typically use bacteriostatic water, combining it with the peptide powder according to the specific requirements of their research protocols.

 

How to dose IGF1-LR3 1mg?

The dosing of IGF1-LR3 1mg in vials form will vary according to the experiment being conducted. We do not provide dosage recommendations as our products are intended for research purposes only.

 

How to administer IGF1-LR3 1mg?

There are multiple methods of administering research products that are under investigation in various studies. The choice of administration technique should align with the specific goals and design of the researcher’s study. We provide products solely for research use, we do not offer advice on administration methods.

0
Spend $150.00 more to get free US shipping
Your Cart is Empty!

It looks like you haven't added any items to your cart yet.

Browse Products
Powered by Caddy